Halozyme Entered into a Definitive Agreement to Acquire Antares for ~$960M
Shots:
- Halozyme to acquire all outstanding shares of Antares for $5.60/share in cash making a total deal value of ~$960M representing a premium of 50% to Antares' share price of $3.74 on 1 day prior. The transaction is expected to be close in H1’22
- The acquisition provides Halozyme access to utilize its Enhanze enzyme-based drug delivery technology with Antares’ auto-injector platform to deliver a range of therapies & drug delivery solutions. The transaction is expected to be immediately accretive to revenue & non-GAAP earnings in 2022 with multiple drivers to boost financial growth through 2027 & beyond
- Antares has developed multiple self-injection products including Xyosted (testosterone enanthate) & Tlando (testosterone undecanoate)
Ref: Halozyme | Image: PR Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
